NYU Langone COVID-19 Research Catalog | NYU Langone Health

Skip to Main Content
Clinical & Translational Science Institute Response to COVID-19 NYU Langone COVID-19 Research Catalog

NYU Langone COVID-19 Research Catalog

NYU Langone researchers rise to meet the challenges of caring for patients with coronavirus disease 2019 (COVID-19). Our scholars are making enormous contributions to knowledge about COVID-19 among the global medical community. Our discoveries range from potential new medications, diagnostics, and devices to novel clinical delivery strategies—including digital health—that promise to render better, safer care for our patients and the world.

We hope researchers use our COVID-19 research catalog to find resources and collaborators in the fight against this global pandemic. For questions about the catalog, please contact Hua (Judy) Zhong, PhD, director, at Judy.Zhong@NYULangone.org or call 646-501-3646. For a full list of all NYU Langone datasets, please see the NYU Data Catalog.

Featured COVID-19 Studies

Researchers at NYU Langone are investigating many aspects of COVID-19. Browse our selection of featured studies or view a complete list of all NYU Langone COVID-19 studies.

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
Primary Investigator: Mila Ortigoza, MD, PhD
Department of Medicine
Sponsor: NYU Langone Health

Site for Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Primary Investigator: H. Michael Belmont, MD
Department of Medicine
Sponsor: Alexion Pharmaceuticals, Inc.

A Single-Center Registry and Embedded Interventional Study of the Effects of COVID-19 with and without Treatment with AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection
Primary Investigator: Stuart D. Katz, MD
Department of Medicine
Sponsor: Leon H. Charney Division of Cardiology

A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Primary Investigator: Mark J. Mulligan, MD
Department of Medicine
Sponsor: Eli Lilly

Multiplatform RTC, A Collaboration Between Three Trial Platforms: Antithrombotic Therapy to Ameliorate Complications of COVID-19; Randomized Embedded Multi-Factorial, Adaptive Platform Trial; Accelerating COVID-19 Therapeutic Interventions and Vaccines
Primary Investigators: Judith S. Hochman, MD; Jeffrey S. Berger, MD
Department of Medicine
Sponsor: Leon H. Charney Division of Cardiology
Read Interim Results and Learn More About the Studies

Site for Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial
Primary Investigator: Anna Bershteyn, PhD
Department of Population Health
Sponsor: Bill and Melinda Gates Foundation

Site for Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): A Blinded, Randomized Study
Primary Investigator: Anna Bershteyn, PhD
Department of Population Health
Sponsor: Bill and Melinda Gates Foundation

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired (REMAP-CAP)
Primary Investigator: Sam Parnia, MD, PhD
Department of Medicine
Sponsor: Global Coalition for Adaptive Research

Off Label Study to Evaluate the Efficacy of Hydroxychloroquine for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers Who are High Risk of Occupational Exposure to SARS-CoV-2
Primary Investigator: H. Michael Belmont, MD
Department of Medicine
Sponsor: Division of Infectious Diseases and Immunology

Treating COVID-19 with Hydroxychloroquine: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Hospitalized Adults
Primary Investigator: Mark J. Mulligan, MD
Department of Medicine
Sponsor: Department of Medicine